16 results on '"Perrotta, Fabio"'
Search Results
2. Clinical Characteristics of "Severe" Peripheral Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort.
- Author
-
Lubrano, Ennio, Scriffignano, Silvia, and Perrotta, Fabio Massimo
- Subjects
PSORIATIC arthritis ,COHORT analysis ,ANKYLOSING spondylitis ,RETROSPECTIVE studies ,DEMOGRAPHIC characteristics - Abstract
Introduction: The concept of severity in a multidomain disease such as psoriatic arthritis (PsA) is still not well defined. The aim of this study was to identify the clinical characteristics of patients with severe peripheral PsA. Methods: Retrospective analysis of a longitudinal cohort. Demographic and clinical characteristics of patients with PsA were collected at baseline and at last follow-up. We defined the severe population using the modified Composite Psoriatic Disease Activity Index (mCPDAI); which excludes ankylosing spondylitis quality of life scale). Hence, patients with a score of 3 in at least one domain were defined as having severe PsA. Clinical characteristics of patients fulfilling the definition of severe PsA were compared to those non-severe. Results: We evaluated 177 patients with peripheral PsA (M/F: 98/76). Of these, 64 (36.1%) were identified as severe according to the mCPDAI criteria, at baseline. Eighteen patients (10.1%) at last follow-up still met the definition of severe PsA. At last follow-up visit, severe patients with PsA were only males (18/18, P < 0.01) and have worse outcomes in terms of disease activity, pain, function, and impact of disease. Male sex and the severity of skin involvement at baseline were factors associated with the presence of severe PsA. The agreement between the presence of severe PsA and the absence of minimal disease activity was slight [Cohen's k: 0.174 (0.084–0.264)]. Conclusions: Our study showed that severe patients with PsA had more disease activity, pain, and impact of disease than non-severe patients. Furthermore, we demonstrated that severity and disease activity are not interchangeable concepts. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment
- Author
-
Navarini, Luca, Caso, Francesco, Costa, Luisa, Currado, Damiano, Stola, Liliana, Perrotta, Fabio, Delfino, Lorenzo, Sperti, Michela, Deriu, Marco A., Ruscitti, Piero, Pavlych, Viktoriya, Corrado, Addolorata, Di Benedetto, Giacomo, Tasso, Marco, Ciccozzi, Massimo, Laudisio, Alice, Lunardi, Claudio, Cantatore, Francesco Paolo, Lubrano, Ennio, Giacomelli, Roberto, Scarpa, Raffaele, and Afeltra, Antonella
- Published
- 2020
- Full Text
- View/download PDF
4. New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review
- Author
-
Perrotta, Fabio Massimo, Musto, Antonio, and Lubrano, Ennio
- Published
- 2019
- Full Text
- View/download PDF
5. Therapeutic Targets for Ankylosing Spondylitis - Recent Insights and Future Prospects
- Author
-
Perrotta, Fabio Massimo, Scriffignano, Silvia, Ciccia, Francesco, Lubrano, Ennio, Perrotta, Fabio Massimo, Scriffignano, Silvia, Ciccia, Francesco, and Lubrano, Ennio
- Subjects
ankylosing spondyliti ,JAK inhibitors ,Rheumatology ,JAK inhibitor ,treatment ,ankylosing spondylitis ,axial spondyloarthritis ,biologic drugs ,axial spondyloarthriti ,biologic drug - Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease belonging to the axial spondyloarthritis (axSpA), a group of diseases that affects the axial skeleton and causes severe pain and disability. An early diagnosis and appropriate treatment can reduce the severity of the disease and the risk of progression. TNF-alpha inhibitors demonstrated efficacy and effectiveness in axSpA patients by reducing disease activity, minimizing inflammation and improving the quality of life. More recently, new insights in pathogenesis of axSpA, including the discovery of the role of IL-23/IL-17 axis and intracellular pathways, led to the development of new biologics and small molecules that improve our therapeutic armamentarium. New alternatives are also being soon available. The aim of this paper is to narratively review the recent insights and future prospects in the treatment of AS and, more in general, axSpA.
- Published
- 2022
6. Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study.
- Author
-
Lubrano, Ennio, Perrotta, Fabio Massimo, Manara, Maria, D'Angelo, Salvatore, Ramonda, Roberta, Punzi, Leonardo, Addimanda, Olga, Salvarani, Carlo, and Marchesoni, Antonio
- Subjects
- *
TUMOR necrosis factors , *ANKYLOSING spondylitis , *DISEASE duration - Abstract
Introduction: The aim of this work is to investigate the improvement of physical function and its determinants in axial spondyloarthritis (SpA) patients treated with tumor necrosis factor (TNF) inhibitors in a real clinical practice setting. Methods: An observational study was conducted in patients with axial SpA treated with anti-TNF from 2010 to 2018 with a minimum 6 months of follow-up. All patients fulfilled ASAS or the modified New York criteria. The Bath Ankylosing Spondylitis Metrology Index (BASMI) and the Bath Ankylosing Spondylitis Functional Index (BASFI) were used as objective and self-reported functional indices. The improvement of function and factors associated were evaluated for the present study, as well as disease activity and patient-reported outcome measures. Results: A total of 183 patients with axial SpA were examined. Among them, 27 were non-radiographic axial SpA, while the remaining 156 were ankylosing spondylitis patients. BASFI and BASMI significantly improved during follow-up. Improvement of metrology index BASMI inverse correlated with disease duration (rho − 0.2, p = 0.009) and directly correlated with the improvement of BASDAI (rho 0.26, p = 0.003) and CRP (rho 0.26, p = 0.0003). Improvement of BASFI significantly inversely correlated with disease duration and directly correlated with the improvement of BASDAI, CRP, and baseline ESR. Male sex, lower disease duration, high ESR, and the improvement of BASDAI were found to be associated with the improvement of BASFI. Conclusions: Our results showed that in real-life settings, patients improve in BASMI and BASFI. Furthermore, factors associated with this improvement were identified. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Role of comorbidities in spondyloarthritis including psoriatic arthritis.
- Author
-
Scriffignano, Silvia, Perrotta, Fabio Massimo, De Socio, Antonia, and Lubrano, Ennio
- Subjects
- *
PSORIATIC arthritis , *HEALTH resorts , *QUALITY of life - Abstract
Spondyloartrhitis (SpA) are a group of diseases characterized by inflammation at articular and entheseal sites. Moreover, patients with SpA suffer from impaired articular function and reduced quality of life. Beyond the articular involvement, SpA and in particular psoriatic arthritis (PsA) are associated with extra-articular manifestations and comorbidities that might increase the burden of the disease. The aim of this article was to review the available evidences on the presence of comorbidities in SpA, including PsA, focusing the attention on the cardiovascular, metabolic aspects, as well as other comorbidities, and their possible management in an integrated manner. Comorbidities in SpA should be carefully evaluated because of their important impact. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.
- Author
-
Perrotta, Fabio Massimo, Ceccarelli, Fulvia, Barbati, Cristiana, Colasanti, Tania, De Socio, Antonia, Scriffignano, Silvia, Alessandri, Cristiano, and Lubrano, Ennio
- Subjects
- *
ANKYLOSING spondylitis , *ANKYLOSING spondylitis treatment , *ANTIRHEUMATIC agents , *BIOTHERAPY , *BONE morphogenetic proteins , *BONES , *QUESTIONNAIRES , *SPINE , *TUMOR necrosis factors , *GENETIC markers , *SEVERITY of illness index , *CASE-control method , *DISEASE progression , *DIAGNOSIS - Abstract
Objective: Several molecules are involved in the pathogenesis of a new bone formation in ankylosing spondylitis (AS). The aim of this study was to evaluate the serum levels of sclerostin in patients with AS as a possible biomarker and to investigate any correlations with radiographic damage, disease activity, and function.Methods: AS patients fulfilled the modified New York criteria, and healthy controls were enrolled for this study. BASDAI, ASDAS-CRP, BASMI, BASFI, patient and physician VAS, and C-reactive protein were evaluated at baseline visit. Spinal damage was assessed using the mSASSS on radiographs performed within 3 months from baseline. Serum concentrations of sclerostin were assessed at baseline and after four months of therapy in patients who started an anti-TNF.Results: Twenty healthy subjects and 40 AS patients were enrolled in the study. In our group, serum sclerostin levels (median (25th-75th percentile)) were significantly higher in healthy controls (18.04 (13.6-24) pg/ml) than in AS patients (6.46 (4.5-11.1) pg/ml; P value < 0.01). However, no significant correlations were found between serum sclerostin levels and radiographic damage, assessed by mSASSS, and between serum sclerostin levels and clinical indices of activity and disability or with laboratory parameters. Sclerostin levels did not show significant changes after 4 months of anti-TNF therapy.Conclusions: The results of our study suggest a possible role of sclerostin in the identification of AS patients. Further studies are needed to prove the role of sclerostin as a disease activity biomarker and progression of disease in AS. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications.
- Author
-
Perrotta, Fabio Massimo, De Socio, Antonia, Scriffignano, Silvia, and Lubrano, Ennio
- Subjects
CYTOKINES ,PSORIATIC arthritis ,DISEASE remission ,THERAPEUTICS ,DISEASE progression - Abstract
Introduction : Remission or low disease activity should be the target of therapy in spondyloarthritis (SpA). Due to the complexity of the disease, several composite indices that assess all disease domains were proposed to define a status of low disease activity/remission in both axial and peripheral SpA. With the introduction, in the past years, of effective biologic and targeted synthetic treatments aimed at inhibiting key cytokines and intracellular pathways, the goal of clinical remission has become an achievable target in these conditions. However, residual disease activity may occur in some domains and the management of patients that achieve the target of remission is still an unmet need.Areas covered : This manuscript aimed to review the current evidence on clinical remission and residual disease activity in SpA (both axial SpA and psoriatic arthritis), and its potential treatment implications.Expert commentary : Progress in our understanding of the pathogenesis of SpA will lead to a rapid increase in the number of available treatments, with the possibility for patients to achieve a status of remission. However, the topic of residual disease activity should be taken into consideration. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
10. Secukinumab for ankylosing spondylitis and psoriatic arthritis.
- Author
-
Lubrano, Ennio and Perrotta, Fabio Massimo
- Subjects
- *
ANKYLOSING spondylitis , *PSORIATIC arthritis , *QUALITY of life , *TUMOR necrosis factors , *DRUG efficacy - Abstract
The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. However, a variable percentage of patients do not respond to anti-TNFα or can exhibit a loss of response and, furthermore, despite anti-TNFα drugs' proven efficacy in reducing peripheral radiographic progression in PsA, the impact in reducing radiographic damage in AS is still debated. Recently, the discovery of new pathogenic mechanisms paved the way to the development of new drugs that target other pro-inflammatory cytokines. In particular, the inhibition of interleukin (IL)-17, which is the principal cytokine produced by Th17 lymphocytes, a pro-inflammatory subset involved in both inflammation and new bone formation in AS and PsA, demonstrated promising results. The new molecule secukinumab, an IL-17A inhibitor, showed its efficacy and safety in phase III randomized clinical trials in AS and PsA and is the first non-anti-TNFα biologic approved for the treatment of AS, providing a useful alternative treatment strategy in both diseases. The aim of this article was to review the pathophysiological basis, the efficacy and the safety of secukinumab treatment in AS and PsA patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
- Author
-
Spadaro, Antonio, Lubrano, Ennio, Marchesoni, Antonio, D’Angelo, Salvatore, Ramonda, Roberta, Addimanda, Olga, Perrotta, Fabio Massimo, Olivieri, Ignazio, Punzi, Leonardo, and Salvarani, Carlo
- Subjects
ACADEMIC medical centers ,ANKYLOSING spondylitis ,BLOOD testing ,CHI-squared test ,FISHER exact test ,MEDICAL cooperation ,MEDICAL records ,RESEARCH ,RESEARCH funding ,STATISTICS ,SURVIVAL analysis (Biometry) ,TUMOR necrosis factors ,DATA analysis ,DISEASE remission ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,CHEMICAL inhibitors - Abstract
Objective. The primary objective of this retrospective study was to investigate the possibility of achieving partial remission (PR) in AS patients treated with anti-TNF-α antagonists, such as adalimumab (ADA), etanercept (ETA) and infliximab (INF), in a real clinical practice setting. Predictors of PR were also evaluated.Methods. A retrospective study was conducted in patients with AS treated with ADA, ETA and INF from 2000 to 2012. Kaplan–Meier survival curves were plotted to determine the rates of PR during the treatment with anti-TNF-α drugs.Results. A total of 283 patients with AS were treated with ADA (18.7%), ETA (26.8%) and INF (54.4%) as first anti-TNF-α drugs, with a PR rate of 57.6%. The probability of obtaining PR with ADA, ETA or INF was not significantly different among all anti-TNF-α patients. AS patients treated with a second anti-TNF-α drug had a PR rate of 40.5%, but after switching for lack of response, the probability of obtaining PR with a second anti-TNF-α drug was significantly lower from that of the first anti-TNF-α drug (P = 0.0039). The probability of obtaining PR in patients with enthesitis (P = 0.04) or psoriasis (P = 0.0016) or low levels of CRP (P = 0.0225) was significantly lower compared with that of patients without these manifestations at baseline.Conclusion. Our real-life study on PR confirmed the effectiveness of ADA, ETA or INF as first or second anti-TNF-α drugs. The presence at baseline of enthesitis or psoriasis or low CRP values yielded a lower probability of obtaining PR. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. Clinical and ultrasonography assessment of peripheral enthesitis in ankylosing spondylitis.
- Author
-
Spadaro, Antonio, Iagnocco, Annamaria, Perrotta, Fabio Massimo, Modesti, Mariagrazia, Scarno, Antongiulio, and Valesini, Guido
- Subjects
ANKYLOSING spondylitis ,ULTRASONIC imaging ,ANALYSIS of variance ,BLOOD testing ,CHI-squared test ,CONFIDENCE intervals ,FISHER exact test ,INFLAMMATION ,PAIN ,TENDINITIS ,U-statistics ,EQUIPMENT & supplies ,VISUAL analog scale ,SEVERITY of illness index ,PROGNOSIS - Abstract
Objective. The aim of this study was to compare clinical examination with power Doppler US (PDUS) in the detection of entheseal abnormalities in patients with AS.Methods. Thirty-six AS patients underwent clinical and PDUS examination of the following bilateral entheseal sites: common extensor tendon at its insertion at the lateral humeral epicondyle; gluteus tendons at their insertion at the greater trochanter; quadriceps tendon at its insertion at the superior pole of the patella; patellar tendon at its proximal insertion at the inferior pole of the patella; patellar tendon at its distal insertion at the tibial tuberosity; Achilles tendon at its insertion at the calcaneus; and plantar aponeuroses at its insertion at the calcaneus.Results. Clinical and PDUS examination revealed at least one abnormal enthesis in 23 (63.9%) and 35 (97.2%) AS patients, respectively. Furthermore, of 432 entheses examined in our 36 AS patients, 64 (14.8%) were considered abnormal by clinical examination and 192 (44.4%) by PDUS. US abnormalities most commonly found were enthesophytes (31.7%), calcifications (33.7%), thickening (29.8%) and hypoechogenicity (26.6%). We found erosions and PD signals in 9.7 and 6% of examined entheseal sites, respectively. The evidence of entheseal abnormalities by clinical examination has a poor likelihood ratio (LR) for the presence of US abnormalities with vascularization (LR = 1.61), without vascularization (LR = 1.24) or erosions (LR = 1.51) at all sites.Conclusions. PDUS permits detection of structural and inflammatory abnormalities of the enthesis in AS and may complement the physical examination in order to better evaluate enthesitis. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
13. Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor-α Drugs: An Italian Multicenter Study
- Author
-
Fabio Massimo Perrotta, Leonardo Punzi, Antonio Marchesoni, Roberta Ramonda, Carlo Salvarani, Salvatore D'Angelo, E. Lubrano, Olga Addimanda, Ignazio Olivieri, Lubrano, Ennio, Perrotta, Fabio Massimo, Marchesoni, Antonio, D'Angelo, Salvatore, Ramonda, Roberta, Addimanda, Olga, Olivieri, Ignazio, Punzi, Leonardo, and Salvarani, Carlo
- Subjects
Male ,Anti-Inflammatory Agents ,Ankylosing spondylitis ,Anti-TNF-αdrugs ,Nonradiographic axial spondyloarthritis ,Remission ,Gastroenterology ,Receptors, Tumor Necrosis Factor ,Etanercept ,Retrospective Studie ,Immunology and Allergy ,Remission Induction ,Anti-TNF-αdrug ,Antibodies, Monoclonal ,Middle Aged ,Anti-Inflammatory Agent ,Treatment Outcome ,Italy ,Nonradiographic axial spondyloarthriti ,Female ,Tumor necrosis factor alpha ,Human ,medicine.drug ,Adult ,medicine.medical_specialty ,Visual analogue scale ,Immunology ,Antibodies, Monoclonal, Humanized ,ANKYLOSING SPONDYLITIS ,ANTI-TNF-α DRUGS ,NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ,REMISSION ,Humans ,Immunoglobulin G ,Retrospective Studies ,Spondylarthritis ,Tumor Necrosis Factor-alpha ,Rheumatology ,Internal medicine ,medicine ,Adalimumab ,Survival analysis ,business.industry ,Spondylarthriti ,Retrospective cohort study ,medicine.disease ,Infliximab ,Ankylosing spondyliti ,Physical therapy ,business - Abstract
Objective.To investigate the possibility of achieving partial remission (PR) in patients with nonradiographic axial spondyloarthritis (nr-axSpA) versus ankylosing spondylitis (AS) treated with anti-tumor necrosis factor (TNF)-α antagonists, such as adalimumab (ADA), etanercept (ETN), and infliximab (IFX), in a real clinical practice setting. The Assessment of SpondyloArthritis international Society (ASAS) 20, ASAS40, and Ankylosing Spondylitis Disease Activity Score were also calculated.Methods.A retrospective study was conducted in patients with axSpA treated with ADA, ETN, and IFX from 2000 to 2013. All patients fulfilled the ASAS or the modified New York criteria. PR was reached when the score was < 20 mm (on a visual analog scale of 0–100 mm) in each of these domains: (1) patient global assessment, (2) pain, (3) function, and (4) inflammation.Results.A total of 321 patients with axSpA were treated. Among them, 62 were nr-axSpA while the remaining 259 were AS. Log-rank test to compare survival curves showed that the probability of obtaining PR in nr-axSpA and AS during treatment with anti-TNF-α was not significantly different. At 12 weeks of exposure to the first anti-TNF-α drug, PR was achieved in 7 patients with nr-axSpA (11.3%) and in 68 patients with AS (26.2%).Conclusion.Our results, obtained from clinical practice, showed that PR is an achievable target of anti-TNF-α treatment in nr-axSpA. The PR rate, as a reliable indicator of sustained effectiveness, is similar in nr-axSpA and in AS.
- Published
- 2014
14. Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: A retrospective study
- Author
-
Salvatore D'Angelo, Leonardo Punzi, Carlo Salvarani, Roberta Ramonda, Ennio Lubrano, Fabio Massimo Perrotta, Antonio Marchesoni, M. Manara, Olga Addimanda, Ignazio Olivieri, Lubrano, Ennio, Perrotta, Fabio Massimo, Manara, Maria, D'Angelo, Salvatore, Addimanda, Olga, Ramonda, Roberta, Punzi, Leonardo, Olivieri, Ignazio, Salvarani, Carlo, and Marchesoni, Antonio
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Immunology ,Severity of Illness Index ,Gastroenterology ,Etanercept ,03 medical and health sciences ,0302 clinical medicine ,Remission anti-TNF-α drug ,Rheumatology ,Interquartile range ,Disease flare ,Internal medicine ,Spondylarthritis ,Adalimumab ,Humans ,Medicine ,Immunology and Allergy ,Axial spondyloarthritis ,Disease flares ,Remission anti-TNF-α drugs ,Antirheumatic Agents ,Female ,Infliximab ,Middle Aged ,Retrospective Studies ,Treatment Failure ,Tumor Necrosis Factor-alpha ,Axial spondyloarthriti ,030203 arthritis & rheumatology ,Ankylosing spondylitis ,medicine.diagnostic_test ,business.industry ,Medicine (all) ,Retrospective cohort study ,medicine.disease ,Surgery ,030104 developmental biology ,Erythrocyte sedimentation rate ,business ,medicine.drug - Abstract
Objective.The aim of this study was to evaluate rate and predictive factors of loss of remission and disease flare in patients with axial spondyloarthritis (axSpA) receiving antitumor necrosis factor (anti-TNF) treatment.Methods.In this retrospective multicenter study, patients with axSpA, according to the Assessment of Spondyloarthritis international Society (ASAS) criteria, treated with adalimumab, etanercept, or infliximab with a minimum followup of 12 months and satisfying the ASAS partial remission criteria and/or Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease were studied. Disease flare was defined as a Bath Ankylosing Spondylitis Disease Activity Index score > 4.5 or ASDAS score > 2.5 on at least 1 occasion.Results.One hundred seventy-four patients with axSpA were studied. After a median [interquartile range (IQR)] followup of 4 years (2–6), 37 patients (21.2%) experienced a loss of remission and 28 (16.1% of the whole study group) a disease flare. Median (IQR) duration of remission in patients who lost this status was 1 year (0.625–2). Higher median erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) values, continuous nonsteroidal antiinflammatory drug (NSAID) use, and an ASDAS-CRP ≥ 0.8 during the remission period were significantly associated with both loss of remission and disease flare. At the multivariate analysis, continuous NSAID intake (OR 4.05, 95% CI 1.4–11.74, p = 0.010) and ESR > 15 (OR 2.90, 95% CI 1.23–6.82, p = 0.015) were the only factors predictive of disease reactivation.Conclusion.In this study, loss of remission and disease flares occurred, respectively, in about 21% and 16% of the patients with axSpA who achieved a state of remission while receiving anti-TNF therapy. Residual disease activity was associated with disease reactivation.
- Published
- 2016
15. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs
- Author
-
Antonio Marchesoni, E. Lubrano, Fabio Massimo Perrotta, I. Olivieri, Leonardo Punzi, Carlo Salvarani, Antonio Spadaro, Salvatore D'Angelo, Roberta Ramonda, Olga Addimanda, Perrotta, Fabio Massimo, Addimanda, O., Ramonda, R., D’Angelo, S., Lubrano, E., Marchesoni, A., Olivieri, I., Punzi, L., Salvarani, C., and Spadaro, A.
- Subjects
Male ,Ankylosing spondylitis, Anti-TNF, Remission ,lcsh:Medicine ,Longitudinal Studie ,Gastroenterology ,Etanercept ,Anti-TNF ,Medicine ,Longitudinal Studies ,BASDAI ,Ankylosing spondylitis ,Remission ,biology ,Remission Induction ,Antirheumatic Agent ,Middle Aged ,Prognosis ,Antirheumatic Agents ,Female ,Human ,medicine.drug ,Ankylosing ,Adult ,medicine.medical_specialty ,lcsh:Internal medicine ,Prognosi ,Rheumatology ,Internal medicine ,Psoriasis ,Adalimumab ,Humans ,Spondylitis, Ankylosing ,lcsh:RC31-1245 ,Tumor Necrosis Factor-alpha ,business.industry ,Infliximab ,C-reactive protein ,lcsh:R ,medicine.disease ,Surgery ,Ankylosing spondyliti ,biology.protein ,business ,BASFI ,Spondylitis - Abstract
The objective of this study was to evaluate the predictive factors for achieving partial remission (PR) in patients with ankylosing spondylitis (AS) treated with anti-TNFα. We longitudinally enrolled in a multi-center study 214 AS patients, classified according to New York criteria, treated with anti-TNFα drugs adalimumab (ADA), etanercept (ETA) and infliximab (INF) with at least 12 months of follow up. PR was reached when the score was
- Published
- 2014
16. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study
- Author
-
Antonio Spadaro, Ignazio Olivieri, Salvatore D’Angelo, Fabio Massimo Perrotta, Carlo Salvarani, Ennio Lubrano, Antonio Marchesoni, Roberta Ramonda, L. Punzi, Olga Addimanda, Spadaro, Antonio, Lubrano, Ennio, Marchesoni, Antonio, D'Angelo, Salvatore, Ramonda, Roberta, Addimanda, Olga, Perrotta, Fabio Massimo, Olivieri, Ignazio, Punzi, Leonardo, and Salvarani, Carlo
- Subjects
Male ,Ankylosing spondylitis ,Anti-TNF-α drugs ,Remission ,Adalimumab ,Adult ,Antibodies, Monoclonal ,Antibodies, Monoclonal, Humanized ,Antirheumatic Agents ,Biomarkers ,C-Reactive Protein ,Drug Evaluation ,Etanercept ,Female ,Humans ,Immunoglobulin G ,Immunosuppressive Agents ,Infliximab ,Kaplan-Meier Estimate ,Middle Aged ,Receptors, Tumor Necrosis Factor ,Remission Induction ,Retrospective Studies ,Spondylitis, Ankylosing ,Treatment Outcome ,Tumor Necrosis Factor-alpha ,Gastroenterology ,Immunosuppressive Agent ,Retrospective Studie ,Monoclonal ,Receptors ,Medicine ,Pharmacology (medical) ,ankylosing spondylitis ,anti-TNF-α drugs ,remission ,Humanized ,biology ,Antirheumatic Agent ,Biological Markers ,medicine.drug ,Human ,Ankylosing ,medicine.medical_specialty ,Antibodies ,Rheumatology ,Psoriasis ,Internal medicine ,Survival analysis ,business.industry ,C-reactive protein ,Retrospective cohort study ,Biomarker ,medicine.disease ,Surgery ,Ankylosing spondyliti ,biology.protein ,Anti-TNF-α drug ,business ,Tumor Necrosis Factor ,Spondylitis - Abstract
Objective: The primary objective of this retrospective study was to investigate the possibility of achieving partial remission (PR) in AS patients treated with anti-TNF-α antagonists, such as adalimumab (ADA), etanercept (ETA) and infliximab (INF), in a real clinical practice setting. Predictors of PR were also evaluated. Methods: A retrospective study was conducted in patients with AS treated with ADA, ETA and INF from 2000 to 2012. Kaplan-Meier survival curves were plotted to determine the rates of PR during the treatment with anti-TNF-α drugs. Results: A total of 283 patients with AS were treated with ADA (18.7%), ETA (26.8%) and INF (54.4%) as first anti-TNF-α drugs, with a PR rate of 57.6%. The probability of obtaining PR with ADA, ETA or INF was not significantly different among all anti-TNF-α patients. AS patients treated with a second anti-TNF-α drug had a PR rate of 40.5%, but after switching for lack of response, the probability of obtaining PR with a second anti-TNF-α drug was significantly lower from that of the first anti-TNF-α drug (P = 0.0039). The probability of obtaining PR in patients with enthesitis (P = 0.04) or psoriasis (P = 0.0016) or low levels of CRP (P = 0.0225) was significantly lower compared with that of patients without these manifestations at baseline. Conclusion: Our real-life study on PR confirmed the effectiveness of ADA, ETA or INF as first or second anti-TNF-α drugs. The presence at baseline of enthesitis or psoriasis or low CRP values yielded a lower probability of obtaining PR. © The Author 2013. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.